Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged over 18 years.
• People who have been confirmed by a tissue biopsy to have one of the following specific types of large B-cell lymphoma: DLBCL not otherwise specified, T cell/histiocyte rich large B-cell lymphoma, EBV-positive DLBCL, Grade 3b Follicular Lymphoma, a mixed lymphoma that includes a DLBCL part with a later DLBCL relapse, or a low-grade lymphoma (such as follicular lymphoma, marginal zone lymphoma, or chronic lymphocytic leukaemia) that has transformed into DLBCL with a later DLBCL relapse.
• People who have received at least one, but no more than three previous treatment regimens for their lymphoma, and at least one of those treatments must have included a therapy that targets a protein called CD20.
• People whose blood test results at the screening stage meet the required laboratory values set by the trial (confirm specific values with trial site).
• People who are willing and able to use an effective barrier method of contraception throughout the trial.
• People who, in the opinion of the treating doctor, are able and willing to receive appropriate prevention or treatment for blood clots, and who can understand and follow the pregnancy prevention safety requirements of the trial.

Who may not be able to join:

• People who have a different type of lymphoma not listed above, whose lymphoma did not respond at all to their very first treatment (primary refractory DLBCL), or who have a history of so-called "double hit" or "triple hit" genetics in their lymphoma.
• People who, within 14 days before the first day of treatment, have not stopped their CD20-targeted therapy, chemotherapy, radiotherapy, or any other experimental or lymphoma-specific treatment.
• People who have had major surgery or a serious injury within 14 days before the first day of treatment.
• People who have received a live vaccine within 14 days before the first day of treatment.
• People who have needed intravenous or injectable antibiotic, antifungal, or antiviral treatment for an active infection within 14 days before the first day of treatment.
• People who have previously been treated with a therapy targeting a protein called CD19, or with a class of drugs called IMiDs (such as thalidomide or lenalidomide).
• People who have had their own stem cells transplanted back into them (autologous stem cell transplant) within 3 months before signing the consent form.
• People who have previously received a stem cell transplant from another person (allogeneic stem cell transplant).
• People who have a history of deep vein blood clots or blood clots in the lungs and who are unwilling or unable to take preventive medication for blood clots throughout the entire treatment period.
• People who are currently receiving any other cancer treatment or participating in another experimental treatment trial.
• People who have a history of any other cancer besides the lymphoma type being studied.
• People who test positive for hepatitis B or hepatitis C.
• People who are known to be HIV-positive or have a history of active HIV infection.
• People whose lymphoma has spread to the brain or spinal cord.
• People who have a significant heart condition, nervous system condition, or other serious health condition that, in the treating doctor's opinion, would make participation unsafe or prevent them from giving informed consent.
• People who have severe liver damage, indicated by a specific liver-related blood test result above a certain level (confirm specific threshold with trial site).

Important: Always verify eligibility with the trial site directly before applying.